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Abstract
Genital Herpes, which is caused by Herpes Simplex Virus-1 or -2 (HSV-1, -2, predominantly HSV-2) is a sexually transmitted
infection (STI) that causes a chronic latent infection with outbreak episodes linked to transmission. Antiviral therapies are
effective in reducing viral shedding during these episodes, but are ineffective as a whole since many outbreaks are
asymptomatic or have mild symptoms. Thus, the development of a vaccine for genital herpes is needed to control this
disease. The question of how to implement such a vaccine program is an important one, and may be similar to the
vaccination program for Human Papilloma Virus (HPV) for young females. We have developed a mathematical model to
describe the epidemiology of vaccination targeting young females against HSV-2. The model population is delineated with
respect to age group, sexual activity and infection status including oral infection of HSV-1, which may affect vaccine efficacy.
A threshold parameter RC , which determines the level of vaccine uptake needed to eradicate HSV-2, is found. Computer
simulation shows that an adolescent-only vaccination program may be effective in eliminating HSV-2 disease, however, the
success of extinction greatly depends on the level of vaccine uptake, the vaccine efficacy, the age of sexual maturity and
safe sex practices. However, the time course of eradication would take many years. We also investigate the prevalence of
infection in the total population and in women between 16–30 years of age before and after vaccination has been
introduced, and show that the adolescent-only vaccination program can be effective in reducing disease prevalence in
these populations depending on the level of vaccine uptake and vaccine efficacy. This will also result in a decrease of
maternal-fetal transmission of HSV-2 infection. Another important, if commonsense, conclusion is that vaccination of some
females reduces infection in men, which then reduces infection in women.
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Introduction
Genital herpes is one of the most prevalent sexually transmitted
infections (STI) in the world. It is estimated that there are 50,000
new cases of genital herpes in Canada per year with approximately
137 new cases each day [1]. The Centers for Disease Control and
Prevention (CDC) estimates that at least 45 million Americans, or
one in five adolescents and adults, have genital herpes infection.
Genital herpes is caused by either herpes simplex virus type 1
(HSV-1) or type 2 (HSV-2), which are transmissible through skin
lesions and mucosa. Once the virus enters a host, it moves from
the skin or mucosa of the genitals to the posterior root into the
sensory ganglia, where it persists as a latent infection for life. Initial
infection results in viral replication in epithelial cells of the genital
tract and then spreads into neurons within the dorsal root ganglia
in which it remains for life (latency) [2]. Virus is released from the
neurons back into the genital tract during reactivations to either a
clinically symptomatic or asymptomatic infection and can be
further transmitted. HSV-1 is commonly associated with oral
infection (herpes labialis or cold sores), but can also cause infection
of the genitals through oral-genital sex, even when an oral sore is
not apparent. HSV-1 genital herpes is increasing in prevalence [3],
however, most genital herpes cases are caused by HSV-2. HSV-2
causes vesicular and ulcerative lesions in adults. Approximately
22% of adults in the USA are HSV-2 positive, approximately 15%
in Europe, as high as 50% in some developing countries in sub-
Saharan Africa, and greater than 50% in countries with a large
HIV positive population [4]. It is estimated that about 1,640,000
HSV-2 seroconversions occur yearly in the USA [5].
Genital herpes can cause recurrent painful genital sores in many
adults, can be severe in people with suppressed immune systems
[6], can cause depression [7], can increase the risk of acquisition of
HIV [8,9], and can cause potentially fatal infections or neurolog-
ical sequelae in newborns from mothers excreting the virus even
asymptomatically at the time of delivery [10]. There is therefore
an urgent need to consider potential control measures for genital
herpes. Antiviral therapies have been shown to be effective in
reducing viral shedding, however, since many cases or episodes of
genital herpes may be unrecognized (asymptomatic or mild
symptoms) antiviral therapies may not be acquired and thus,
these drugs can not be effective in controlling HSV transmission in
general. Also, if high adherence rates (w90%) to an antiviral
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regimen are not maintained, transmission rates can increase [11].
The correct and consistent use of condoms can decrease the risk
for HSV-2 acquisition [12]. However, since genital herpes is
transmitted by skin-to-skin contact, condoms are not 100 percent
protective. Using sexual or other risk factors to screen and identify
individuals at higher risks of infection, so as to target interventions,
however, may not be feasible or ethically acceptable [13].
Developing an effective HSV-2 vaccine would be a suitable
strategy to prevent and control genital herpes infections [4].
Recently, HerpevacTM a potential vaccine developed by GSK
failed in Phase III clinical trials [14]. Currently, the Im-
munoVEXHSV2 vaccine by Biovex and the ACAM-529 vaccine
supported by Sanofi Pasteur are undergoing clinical trials [15,16].
However, these clinical trials are in very early phases and it is
unknown how such vaccines will protect individuals from infection
of HSV-2.
Mathematical models of infectious diseases have proven to be a
valuable component of public health planning and response. Such
models can be employed to evaluate whether a vaccination
program will be effective in eliminating a pathogen, or controlling
a disease. Such studies can be done prior to the introduction of a
vaccine, so as to determine the most effective strategy of
vaccination coverage. Mathematical models have been developed
to provide insight on the long-term epidemiologic consequences of
vaccination against HSV-2 [17–21]. However, these models have
made some simplifying assumptions which ignore some key
characteristics of HSV-2 transmission.
First, they have ignored any differences in HSV-2 transmission
or infection by age. The risk of HSV-2 infection is closely related
to the sexual behaviour of different age groups. The National
Health and Nutrition Examination Survey (NHANES), a series of
cross-sectional national surveys from 1976 to 2004 conducted by
the National Center for Health Statistics, found that overall HSV-
2 seroprevalence rises rapidly in younger age groups and then
remains stable among those older than 30 years, in the range of 24
percent to 28 percent prevalence [22,23]. However, HSV-2
prevalence is negligible among persons who have never been
sexually active [24].
Second, except for [19], they have ignored the fact that the risk
of acquiring genital herpes also varies by gender. Females are at a
greater risk of acquiring genital herpes from male partners than
males are from females partners [22,25]. Seroconversion rates are
also much higher for females [26].
Third, some models have focussed on assessing the effectiveness
of adult vaccination against HSV-2 [18–21]. However, infection
with HSV-1 (oral or genital) may prove an HSV-2 vaccine
ineffective [19,27]. This causes a major problem since HSV-1 is
highly prevalent as an oral infection in adults [23,28]. Thus, it may
be reasonable to target the vaccination program at children where
HSV-1 infection is relatively low [29].
The childhood vaccination program has had substantial impact
on the control of many infectious diseases that were once common
in the world. Recently, the HPV vaccination program was
introduced into the childhood vaccination progarm as an
adolescent-only vaccine being targeted mainly at young girls prior
to adolescence and age of onset of sexual activity [30]. The recent
HPV immunization routine program is recommended for girls
aged 9–14 years in Canada, girls aged 11–12 years in USA, aged
12–13 in UK and girls aged 12 in Italy [30]. Incorporating a
vaccine against HSV-2 in this program could be done if it is
deemed beneficial.
In this paper, we develop a mathematical model to evaluate the
effectiveness of a vaccination program against HSV-2. We focus
our study on a vaccination program targeting female school
children aged 12–14 years. Our model also includes age structure
and gender differences in transmission. We also include varying
efficacies of the vaccine against HSV-2, which may not be effective
in individuals that are HSV-1 positive. The details of our model
and model assumptions are outlined in the next section.
Methods
The mathematical model, shown in Fig. 1, illustrates how
genital herpes can spread in a population. The population is
divided into compartments depending on gender (male or female),
disease status (infected or uninfected), and susceptibility to the
virus (superscript m denotes protection). The female population is
then further divided according to age (children 13–16 years old
(C), and adults between 16–30 years of age (A) and over 30 years
of age (O)) [22,23] and vaccination status (vaccinated or
unvaccinated). Note that age stratification is only applied to the
female population since an adolescent vaccination program for
females only, similar to the current HPV vaccination programs
adopted in many countries around the world, is being considered.
The mathematical model can be described as follows: female
children (C) enter the population at rate l1. Female children that
are HSV-1 seronegative (c), vaccinated (p) and acquire immunity
from the vaccine (E) move to the vaccinated/protected class CV
and all others remain in the non-immune class (CU ). Since several
vaccine trails have shown some success in preventing disease, but
only in females that are HSV-1 and -2 negative, we incorporate
here the HSV-1 seronegative proportion c to account for this
possible vaccine limitation [27]. It is assumed that vaccination
induces lifelong immunity. The non-immune and immune female
children (CU and CV respectively) proceed to the susceptible and
protected adult female classes 16–30 years old (AS and A
m
S
respectively) at rate a1 and these individuals mature at rate a2 to
the older female susceptible and protected classes aged 30 years
and older (OS and O
m
S respectively). It is assumed that susceptible
females (AS and OS ) also proceed (d) to the protected classes (A
m
S
and OmS ) reflecting a change in sexual activity in which they leave
the at risk class (i.e. marriage). Susceptible females AS and OS are
infected with HSV-2 by infected men (MI ) at rates bMA and bMO
respectively. Infected females AI and OI can then, in turn, infected
susceptible males (MS ) at rates bAM and bOM respectively.
Infected adult females (AI ) mature at rate a2 to the older female
infected class (OI ). Like the susceptible females (AS and OS ),
infected females (AI and OI ), susceptible males (MS ) and infected
males (MI ) can also change sexual behaviour and move to the A
m
I ,
OmI , M
m
S and M
m
I classes respectively. Children and adults die at
rate m and susceptible males enter the population at rate l2. The
model equations are written in the Appendix S1.
It is assumed that the incidence rates (the rate of new infections)
are proportional to the transmission probability of HSV-2 per
sexual partnership and the average number of new sex partners
acquired per year, but are inversely proportional to total number
of sexually active population [31,32]. We further assume that
female individuals who are not covered by the vaccine program
have the same rate of transmission as those who are vaccinated but
do not gain immunity against infection. This assumption is based
on the following two observations: (1) vaccinated females may have
a greater level of sexual activity (higher c) because they feel
protected from infection [33]; (2) infectivity during outbreaks may
be reduced and outbreaks may occur less often in vaccinated
individuals (lower b) [34].
We model latent and infectious populations together in this
framework. The inclusion of latent infections in the infected
A Vaccine against HSV-2 for Young Females
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compartment is reflected by a low transmission rate (see Appendix
S1). This allows for a more attractive model for analytical study.
Parameter Values
Parameter values are listed in Table 1 and are chosen so that
they agree with current Canadian and North American statistics,
and data reported in the medical literature. The mortality rate is
assumed to be approximately 1=82 years21, where 82 years is the
mean life expectancy of Canadians between 2000–2006 [35]. It is
assumed that the vaccine will only be effective in 50% of the
female children aged 13 years, which are HSV-1/HSV-2
seronegative (c) [36]. Vaccine uptake (p) is assumed to lie in the
range of 53{80% which is similar to the range reported for the
adolescent vaccination program against HPV [37]. Immunogene-
city (E) is variable (0{100%).
It is assumed that the average age of progression of female
children to sexual activity (a1) is between 15{18 years [38], that
young adult females progress to the older adult female class at rate
a2~1=14 years
21 (see [22,23]), and that adult females and males
remain in the ‘effective’ sexually active population for an average
of 10{20 years (d, time span for selecting new partners) [39]. This
agrees with statistics from the National Survey of Family Growth
[40] and the Canadian Community Health survey [41] whereby
individuals 25{34 years of age have a higher probability of
entering into monogamous relationships, and that the probability
of sexual activity out of these monogamous relationships is small.
Similar to [42], we calculate the maturation rate of female
children to sexually active young adults:
1
d
z
1
a1
~15{18 years
where 1=d~10{20 years [39] and thus, a1w1=8 years21.
Females have a greater risk of acquiring genital herpes from
male partners than males do from female partners [22,25]. It is
assumed that bMAwbAM and bMOwbOM , where the b’s are
related to transmission probabilities per sexual partnership and the
average number of sex partners by age. Parameters are chosen so
that the prevalence of HSV-2 in men and women is about 21%, in
line with Canadian and North American estimates [22,36,43].
Results
Control Threshold
The basic reproductive ratio, R0, defined as a the number of
secondary infections produced by a single infective in a totally
susceptible population, is a quantity that determines whether a
given disease may spread, or die out in a population. If R0v1 then
the disease will die out, however, if R0w1 then it will increase in
the population. A second quantity called the control reproductive
ratio, RC , can be used to determine whether a control policy, such
as vaccination, will be successful in reducing the number of
secondary infections to be less than one. For a review of methods
to calculate R0, see [44].
Applying the survival function method [44,45], RC can be
rewritten as:
RC~
A
N
bMA
dzm
M
N
bAM
dza2zm
z
A
N
bMA
dzm
M
N
a2
dza2zm
bOM
dzm
z
O
N
bMObOM
(dzm)2
M
N
ð1Þ
and
R0~RC=(1{Ecp): ð2Þ
The threshold RC can be explained relative to the underlying
biology as follows: when an infective male is introduced into the
population, new infected males can be made through three
possible pathways:
One infected male{{{{{{?
contact with AS
AI {{{{{{?
contact with MS
MI;
One infected male{{{{{{?
contact with AS
AI {{{{?
grow older
OI {{{{{{?
contact with MS
MI;
One infected male{{{{{{?
contact with OS
OI {{{{{{?
contact with MS
MI:
Figure 1. Disease transmission diagram.
doi:10.1371/journal.pone.0046027.g001
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which correspond to the first, second and third terms of Eq. (1)
respectively. For instance, using the second path, we see that when
one infected male is introduced into the population, the male
produces, on average, bMA
A
N
1
dzm
infected young adult females
aged 16–30 years during his average sexual lifespan (1=(dzm)).
These young adult females then grow into adult females aged 30
years and older over their lifespan 1=(dza2zm) at a rate a2 and
then each infected older adult female produces, on average,
bOM
M
N
1
dzm
infected males during her sexual lifespan 1=(dzm).
Thus through the second path, the average number of new
infected males produced by a single infected male in a population
consisting only of susceptible females and males is
bMA
A
N
1
dzm
bOM
M
N
a2
dza2zm
1
dzm
. With the parameter values
listed in Table 1, the basic reproduction number R0 is 1:6495, that
is, one infected male makes 1.65 new infected males (or 1 infected
female makes 1.65 new infected females) when this individual is
introduced into a population composed only of susceptible males
and females. If we assume the parameters related to a vaccine
program are E~60%, c~50%, and p~80%, then the reproduc-
tion number RC becomes 1:2536.
Note that a reduction in the infectivity (b’s) will also decrease
RC . Moreover, in order to eradicate HSV-2 from a population,
the vaccination program must be effective in reducing RCv1 (see
Theorem A3 in Appendix S1 for theoretical results). From Eq. (2)
we find that this will occur when a critical vaccination threshold
(pc) is achieved, where
Table 1. List of notations and symbols.
Symbol Definition Parameter Parameter Reference
value used range
CU Non-immune females aged 12 years
CV Vaccinated girls with immunity
aged 12 years
AS Susceptible females aged 16–30 years
AI Infected females aged 16–30 years
OS Susceptible females aged over 30 years
OI Infected females aged over 30 years
MS Susceptible males
MI Infected males
l1 Female population birth rate 27 calculated
l2 Male population birth rate 30 calculated
E Efficacy of vaccine in girls 0{100%
c Proportion of females by age 12 that are 50% 0{100% [36]
HSV-1 and HSV-2 seronegative
p Proportion of females vaccinated 53{80% 0{100% [37]
with HSV-2 vaccine by age 12
a1 Maturation rate (per year) from children 1
4
w1=8 calculated
to young adults
a2 Leaving rate (per year) from young adults 1
14
[22,23]
to older adults
m Mortality rate (per year) 1
82
[35]
1=d Average length of sexual life span (i.e. time 10 10{20 [39]
span for acquiring new sex partners) (years)
bMA Transmission rate (per year) from an infected male 2.82 calculated
to a female (16–30 years of age) [22,25,36,43]
bMO Transmission rate (per year) from an infected male 3 calculated
to a female (over 30 years of age) [22,25,36,43]
bAM Transmission rate (per year) from an infected female 2.52 calculated
(16–30 years of age) to a male [22,25,36,43]
bOM Transmission rate (per year) from an infected female 2.58 calculated
(over 30 years of age) to a male [22,25,36,43]
doi:10.1371/journal.pone.0046027.t001
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pc~
1
Ec
1{
1
R0
 
: ð3Þ
Numerical Simulations
An adolescent-only vaccination program may be effective in
eliminating HSV-2 (Fig. 2). However, regardless of the vaccine
efficacy and uptake, the time course of eradication would take
many decades (Fig. 3). Also eradication may not result (Fig. 3). For
similar vaccination uptake to that of the HPV vaccination
program (53–80%), HSV-2 elimination may not be achieved
Figure 2. Prevalence of HSV-2 with different levels of
vaccination. Prevalence of HSV-2 decreases as vaccine uptake
increases in the total population (solid line), women ages 16–30 years
(dot-dashed line), women ages over 60 years (dashed line), women ages
over 16 years (black dotted line) and men (gray dotted line). Vaccine
efficacy (E) levels are assumed to be 95% (a) and 60% (b) respectively.
The proportion of females by age 12 that are HSV-1 and HSV-2
seronegative (c) is assumed to be 50%.
doi:10.1371/journal.pone.0046027.g002
Figure 3. Prevalence of infection over time. Prevalence of infection
in the total population (top), women ages over 16 years (bottom left) and
men (bottom right) are shown when vaccination is started at year 1 and is
given for 999 years. Vaccination levels, from top to bottom, are 0, 10, 20, 30,
40, 50, 60, 70, 80, 90 and 100%. Vaccine efficacy (E) is assumed to be 95%
and the proportion of females by age 12 that are HSV-1 and HSV-2
seronegative (c) is assumed to be 50%.
doi:10.1371/journal.pone.0046027.g003
A Vaccine against HSV-2 for Young Females
PLOS ONE | www.plosone.org 5 October 2012 | Volume 7 | Issue 10 | e46027
(Fig. 4a, solid line). If vaccine efficacy is w95%, or if the
proportion of children that are HSV-1/HSV-2 negative decreases
(c), then eradication is more likely, but high vaccination uptake is
still required (Fig. 4a). An important, if commonsense, conclusion
is that vaccination of some females reduces infection in men,
which then reduces infection in women (Fig. 3b,c).
To aid in the reduction of HSV-2 prevalence, education
programs about genital herpes may be implemented. These
programs will have an important effect if vaccination uptake or if
the efficacy of the vaccine is low. A possible effect of these
programs is an increase in the average age of progression of
children to sexual activity. Fig. 4b demonstrates that as the average
age of sexual maturity (13z1=a) increases, the proportion of
females needed to vaccinate to eradicate HSV-2 decreases.
However, eradication without vaccination would not be feasible
since it is impossible for the age of sexual maturity to be high
(Fig. 4b) as populations would not be sustained. Also, even with
high levels of efficacy (E) vaccination is unlikely to eradicate HSV-2
since very high levels of vaccine uptake, which are greater than
what is seen in HPV, are required.
Another possible effect of education programs is an increase in
safe sex practices. This includes the use of condoms, and can
include the use of antivirals in those infected with HSV-2. The use
of condoms have been routinely recommended for the prevention
of transmission of sexually transmitted diseases such as HSV-2
[12], especially in the absence of vaccine. The correct and
consistent use of condoms can greatly reduce a person’s risk of
acquiring HSV-2 [12]. Daily suppressive therapy can also reduce
the risk of HSV-2 transmission by up to 50% [46]. Fig. 4c
demonstrates that if safe sex practices reduce infectivity (b’s) to
78% or lower then HSV-2 can be eradicated. However, this result
is hampered by the fact that genital herpes can be transmitted even
when condoms and/or antivirals are use [46]. Also, this figure
assumes that safe sex practices are equally effective in the
prevention of infection of females and males. Therefore, the
vaccination coverage reported here is simply a lower bound that
needs to be achieved in a population where condoms are
consistently used.
From the above examples it was shown that eradiction of HSV-
2 will be very difficult to obtain. The goal of the vaccination
program can then be to decrease disease prevalence in the
population. Fig. 5 shows the proportion of children needed to
vaccinate so that the prevalence of infection can be reduced by 0–
100%, for three different levels of vaccine efficacy. This figure
demonstrates that for similar vaccination uptake to that of the
HPV vaccination program (53–80%), HSV-2 prevalence can be
reduced by 30{90%, however, this reduction in prevalence can
still take many decades to achieve (Fig. 3).
Pregnant females infected with genital HSV-2 (particularly
those with a primary infection) can transmit infection to the
neonate, which can lead to serious neonatal complications, such as
neurologic problems and even death. Thus, it is important to
consider the impact of vaccination on the prevention of HSV-2 in
the child-bearing age group. Fig. 2 shows the prevalence of
infection in women over 16–30 years of age before and after
vaccination has been introduced (dot-dashed line). Since the
majority of pregnant mothers are from this age group, this
demonstrates that the adolescent-only vaccination program results
in a decrease in the number of infected pregnant females. This will
in turn result in a decrease of maternal-fetal transmission of HSV-
2 infection.
Intensive sensitivity analyses can be performed in various ways
to determine which parameters play a major role in affecting the
predicted results. We perform the sensitivity analysis by using the
Figure 4. Thresholds of vaccination. Vaccination thresholds for
eradication pc depend on the efficacy of the vaccine (top), age of sexual
maturity (bottom left) and rate of transmission (bottom right). (a)
Threshold curves depending on vaccine efficacy for three levels of HSV-
1 and HSV-2 negative children (c~50, 65 and 95%, solid line, dashed
line, dot-dashed line respectively) at the time of vaccination. All lines
A Vaccine against HSV-2 for Young Females
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Latin Hypercube Sampling (LHS) process, which is numerically
computed using the method described in [47,48]. In the LHS
method, by using a uniform distribution, values are chosen
randomly without replacement from each of the 9 parameters in
specified ranges. Following this procedure, for each of these
parameters, a partial rank correlation coefficient (PRCC) value is
calculated. PRCC values provide a measure of the relationship
between model inputs and outputs and are particularly useful for
such relationships that are nonlinear but monotonic. PRCC values
range between 21 and 1 with the sign determining whether an
increase in the parameter value will decrease (2) or increase (+)
the specified model output. The PRCC results for disease
prevalence in the total popualtion are shown in Fig. 6. This figure
indicates that the transmission rates b and parameters related to
the vaccination programs (c, E, p) are statistically significant (with
DPRCCDw0:5). In contrast, the progression rates a1 and a2 are
relatively insignificant. These results highlight the importance of
vaccine uptake, vaccine efficacy, HSV-1 and HSV-2 status, and
safe sex in the control of genital herpes. The PRCC results for
HSV-2 prevalence in men, adult and older women, and the
control reproduction number are similar to that shown in Fig. 6.
Discussion
Genital herpes is one of the most prevalent sexually transmitted
diseases in the world. Currently, the development of a vaccine
agsint HSV-2, the main cause of genital herpes, is a major focus of
study. We have developed a model of HSV-2 transmission that
delineates the population by gender and age, two factors that have
been shown to be effective predictors of HSV-2 risk, to assess the
efficacy of a vaccination program against HSV-2 similar to the
vaccination program already implimented against HPV. Using
this model we have found that eradication of HSV-2 may be
achievable, however, this feasibility of eradication depends on
several factors.
Firstly, eradication greatly depends on the rate of vaccine
uptake and the efficacy conferred by the vaccine. Vaccine uptake
needs to be very high (w80%) even if the vaccine is very effective
in inducing protection against the disease. However, even if
vaccine uptake is high, eradication will not be seen for several
decades.
The possibility of eradication also depends on education
programs that may delay the age of sexual maturity and increase
the level of safe sex practices. In these cases, however, vaccination
uptake still needs to be very high and may exceed what is actually
achievable.
Although eradication will be difficult to achieve, the vaccination
program can be effective in reducing disease prevalence to a large
extent. Reduction levels of 30{90% can be achieved, however,
these also greatly depend on the vaccine efficacy and the time
since the initiation of the vaccination program.
An extension of the current model may be to study the effects of
vaccination in age groups less than 14 years of age (and perhaps
infants) where HSV-1 prevalence is decreased, and study the
effects of a vaccine that is only partially affected by HSV-1
prevalence. Both of these scenarios can be compared to a variation
in parameter c. Using the current model we see that the
proportion of children needed to vaccinate to eradicate HSV-2
is decreased considerably when c increases.
Another future direction may be to study the effects of booster
vaccines in adult females, since vaccine induced immunity to
HSV-2 may wane over time. Further delineation of the population
including oral infection versus genital infection and sexual
preference may also be important when considering the number
of booster vaccinations required and the time between them.
A limitation of the current model is we do not model varying
rates of virus shedding. HSV-2 infection is actually characterized
by rapid episodes of asymptomatic shedding punctuated by
denote threshold corresponding to a vaccine immunogenecity of 95%.
(b) Threshold curves depending on age of sexual maturity for three
levels of vaccine efficacy (E~50, 70 and 90%, dashed line, solid line, dot-
dashed line respectively) The vertical line at age 25 represents the
maximum age at which age of sexual maturity could be achieved to
sustain a population. (c) Threshold curves depending on reduced
transmission rates (qbi , q~0:7 to 1:0) for three levels of vaccine efficacy
(E~50, 70 and 90%, dashed line, solid line, dot-dashed line
respectively).
doi:10.1371/journal.pone.0046027.g004
Figure 5. Reduction in prevalence. Vaccination thresholds for
reduction in prevalence by 0{100% are shown for three different levels
of vaccine efficacy (E~ 50, 70 and 90%, dashed line, solid line, dot-
dashed line respectively).
doi:10.1371/journal.pone.0046027.g005
Figure 6. Senstitivity analsysis. The partial rank correlation
coefficients are shown using the total population as the index.
doi:10.1371/journal.pone.0046027.g006
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increased quantities of virus [2,49]. Inclusion of varying rates of
viral shedding a course for future work.
In this study it is assumed that the HSV-2 vaccine can induce
protection in vaccinated individuals, thereby preventing infection.
Development of a vaccine against HSV-2 that could provide
protective immunity is thought to be unrealistic. The goals in
vaccine development against HSV-2 have been to (1) prevent the
establishment of latent infection, (2) to reduce the severity of the
symptoms, and (3) to reduce the frequency of recurrences [50].
Therefore, our results provide a best case scenario of what could
be achieved, and suggest that eradication of HSV-2 would not be
possible with vaccines that merely decrease symptoms and the
frequency of recurrences, since transmission is still possible in these
instances.
Supporting Information
Appendix S1 Mathematical analysis of the model. The
mathematical model is formulated as a system of ordinary
differential equations. We find the model equilibria, the basic
reproductive ratio, and provide some local and global stability
analysis of the model. Justification of the SI framework is also
provided.
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